Final Program

MONDAY • MAY 16 231
404 Metformin Suppresses Myofibroblast Differentiation by
Inhibition of NOX4-Mediated SMAD Signaling/N. Sato, N.
Takasaka, M. Yoshida, S. Minagawa, J. Araya, N. Saito, K.
Tsubouchi, Y. Kurita, K. Kobayashi, H. Hara, J. Kojima, T. Numata,
Y. Kaneko, K. Nakayama, T. Morikawa, K. Kuwano, Tokyo, Japan,
p.A4534
405 The Proteome Signature of Disease Progression in Idiopathic
Pulmonary Fibrosis/D.N. O’Dwyer, S. Ashley, M. Xia, S. Murray,
E. Grant, E.S. White, K.R. Flaherty, F.J. Martinez, B.B. Moore, Ann
Arbor, MI, p.A4535
406 Alveolar Type II Cell Transplantation Improves Alveolar
Dynamics and Structure in Bleomycin Induced Lung
Fibrosis/G. Gay-Jordi, E. Lopez-Rodriguez, M. Ochs, A.
Serrano-Mollar, Barcelona, Spain, p.A4536
407 Thyroid Hormone as a Novel Therapeutic Agent in Lung
Fibrosis Through Restoration of AECs Mitochondrial
Homeostasis/G. Yu, A. Tzouvelekis, R. Wang, J. Herazo-Maya,
J.P. Castro, G. DeIuliis, T. Woolard, R. Drigo, R. Homer, A.
Srivastava, Y. Gan, M. Graham, X. Liu, P. Mannam, E. Herzog, A.
Antonio C. Bianco, N. Kaminski, New Haven, CT, p.A4537
408 Disease Progression in Idiopathic Pulmonary Fibrosis Is
Associated with an Increased Subpopulation of Resident
Pulmonary Monocyte Like Cells in Bronchoalveolar
Lavage/L.M. Nicol, M. Brittan, J.A. Marwick, A.C. MacKinnon, R.
Mills, P.A. McFarlane, W.A. Wallace, G. Stewart, J. Simpson, A.
Rossi, S.E. Howie, J.T. Murchison, N. Hirani, Edinburgh, United
Kingdom, p.A4538
409 Azithromycin Suppresses TGF-ß-Induced Myofibroblast
Differentiation by Promoting Proteasomal Degradation of NOX4/K.
Tsubouchi, J. Araya, H. Hara, S. Minagawa, N. Saito, N. Sato, M.
Yoshida, Y. Kurita, K. Kobayashi, J. Kojima, T. Numata, Y. Kaneko, K.
Nakayama, T. Morikawa, K. Kuwano, Tokyo, Japan, p.A4539
410 miR338-3p, a Target of Lactate Dehydrogenase, Is Differentially
Regulated in Pulmonary Fibrosis/J.L. Judge, C.F. Woeller, T.H.
Thatcher, R.P. Phipps, P.J. Sime, R.M. Kottmann, Rochester, NY,
p.A4540
411 Self-Assembled Micelle RNAi for Effective and Safe Targeting
of Dysregulated Genes in Pulmonary Fibrosis/P.O. Yoon, J.W.
Park, C.-M. Lee, S.H. Kim, J.-S. Yang, H.-O. Park, K. Lee, Q. Lu,
J.A. Elias, C.G. Lee, Daejeon, Korea, Republic of, p.A4541
412 The Effect of Inhaled Low Dose Carbon Monoxide on
Cytokine/Chemokine Production in Idiopathic Pulmonary
Fibrosis/K.T. Rooney, H.J. Goldberg, G.M. Hunninghake, K. Nakahira, I.I.
Siempos, K.R. Flaherty, F.J. Martinez, J.G.N. Garcia, D.J. Lederer, J.C.
Osorio, G. Raghu, J.A. Villalba, J. Lasky, H.R. Collard, I. Noth, R.F.
Machado, C. Steele, I.O. Rosas, A.M.K. Choi, New York City, NY, p.A4542
413 Pathogenesis of Pulmonary Fibrosis - The Role of Extracellular
Heat Shock Protein-90 (HSP90) in Myofibroblast Differentiation
and Persistence/P.-S. Bellaye, N. Wheildon, C. Shimbori, M.R.J.
Kolb, Hamilton, Canada, p.A4543
414 De Novo Analysis of Human Idiopathic Pulmonary Fibrosis
Lungs Reveals Dysregulated Canonical A-to-G Editing Events
at 3’ UTRs and microRNA Target Sites/R. Soundararajan, T.M.
Stearns, A.L. Griswold, A. Mehta, A. Czachor, J. Fukumoto, R.F.
Lockey, B.L. King, N. Kolliputi, Tampa, FL, p.A4544
415 Effects of Nintedanib and Pirfenidone on Expression and
Maturation of Collagen -a Comprehensive Analysis/L. Knuppel,
Y. Ishikawa, K. Heinzelmann, R. Hatz, J. Behr, H.P. Bachinger, O.
Eickelberg, C.A. Staab-Weijnitz, Munchen, Germany, p.A4545
416 Critical Importance of the ROCK Isoforms ROCK1 and ROCK2
for Vascular Leak and Dendritic Cell Recruitment in Pulmonary
Fibrosis/R.S. Knipe, C.K. Probst, J.W. Griffith, B.S. Shea, J.K.
Liao, A.M. Tager, Boston, MA, p.A4546
417 MUC5B And TOLLIP Variants: Association with Disease
Progression And Survival in an IPF Cohort/C. Stock, M. Bonini,
S. Kingston, G.E. Lindahl, A.-M. Russell, P.L. Molyneaux, P.
Saunders, M.A. Kokosi, P. Sestini, A.U. Wells, T.M. Maher, E.A.
Renzoni, London, United Kingdom, p.A4547
418 Oral Treatment with PBI-4050 Reduces Serum and Lung
Anti-Inflammatory/Fibrotic Biomarkers/L. Gagnon, B. Grouix, M.
Tremblay, A. Laverdure, L. Gervais, F. Sarra-Bournet, L. Geerts, K.
Hince, M.-P. Cloutier, M. Leduc, S. Abbott, J.-S. Duceppe, B.
Zacharie, P. Laurin, Laval, Canada, p.A4548
419 Amelioration of Pulmonary Fibrosis by Targeting the Unfolded
Protein Response/M. Thamsen, B.J. Backes, F.R. Papa, San
Francisco, CA, p.A4549
420 MUC5B Promoter Polymorphism rs35705950 Enhances the
Risk of Asymptomatic Fibrotic Interstitial Lung Disease/S.K.
Mathai, A.D. Walts, J. Powers, D.A. Lynch, J.H. Chung, K. Smith,
J. Woodward, J. Loyd, K.K. Brown, M.P. Steele, M.I. Schwarz, T.
Fingerlin, I.V. Yang, D.A. Schwartz, Aurora, CO, p.A4550
421 Treatment with a Selective KCa3.1 Ion Channel-Inhibitor
Attenuates Established Pulmonary Fibrosis in a Segmental
Bleomycin Challenge Model in Sheep/L. Organ, E.
Koumoundouros, B. Bacci, C. Samuel, W. Kimpton, K. Snibson,
Parkville, Australia, p.A4551
422 Administration of Sphingosine Kinase 1 Inhibitor
Post-Bleomycin Challenge Attenuates Bleomycin-Induced
Pulmonary Fibrosis in Mice: Role of YAP1/L.S. Huang, V.
Natarajan, Chicago, IL, p.A4552
423 Non Circulating Pulmonary Resident Memory T Cells Can Be
Identified And Demonstrate Activated Phenotypes in Idiopathic
Pulmonary Fibrosis/C. Bonham, C.L. Hrusch, M. Jaffery, A.
Adegunsoye, K. Blaine, M.E. Strek, I. Noth, A.I. Sperling, Chicago,
IL, p.A4553
424 XBP1 Deficiency in Type II Alveolar Epithelial Cells Protects
Against Lung Fibrosis/J. Brands, M. Bueno, M. Rojas, A.L. Mora,
Pittsburgh, PA, p.A4554
425 Targeting Fibroblastoid-Like Cells by Drug Loaded Engineered
Gold Nanoparticles as Novel Approach for ILD-SSc
Treatment/F. Meloni, E. Cova, S. Inghilleri, V. Codullo, L. Pandolfi,
D. Piloni, M. Colombo, M. Morosini, V. Barzon, S. Magni, D.
Prosperi, C. Montecucco, Pavia, Italy, p.A4555
MONDAY AFTERNOON
ATS 2016 • San Francisco